375 related articles for article (PubMed ID: 31521117)
1. In search of potential predictors of erythropoiesis-stimulating agents (ESAs) hyporesponsiveness: a population-based study.
Ingrasciotta Y; Lacava V; Marcianò I; Giorgianni F; Tripepi G; D' Arrigo G; Chinellato A; Ugo Tari D; Santoro D; Trifirò G
BMC Nephrol; 2019 Sep; 20(1):359. PubMed ID: 31521117
[TBL] [Abstract][Full Text] [Related]
2. Comparative Effectiveness of Biosimilar, Reference Product and Other Erythropoiesis-Stimulating Agents (ESAs) Still Covered by Patent in Chronic Kidney Disease and Cancer Patients: An Italian Population-Based Study.
Ingrasciotta Y; Giorgianni F; Marcianò I; Bolcato J; Pirolo R; Chinellato A; Ientile V; Santoro D; Genazzani AA; Alibrandi A; Fontana A; Caputi AP; Trifirò G
PLoS One; 2016; 11(5):e0155805. PubMed ID: 27187174
[TBL] [Abstract][Full Text] [Related]
3. Predictors of hyporesponsiveness to erythropoiesis-stimulating agents in hemodialysis patients.
Kalantar-Zadeh K; Lee GH; Miller JE; Streja E; Jing J; Robertson JA; Kovesdy CP
Am J Kidney Dis; 2009 May; 53(5):823-34. PubMed ID: 19339087
[TBL] [Abstract][Full Text] [Related]
4. Use of erythropoiesis-stimulating agents among chemotherapy patients with hemoglobin exceeding 12 grams per deciliter.
Nordstrom BL; Luo W; Fraeman K; Whyte JL; Nordyke RJ
J Manag Care Pharm; 2008; 14(9):858-69. PubMed ID: 19006442
[TBL] [Abstract][Full Text] [Related]
5. Prevalence, treatment status, and predictors of anemia and erythropoietin hyporesponsiveness in Japanese patients with non-dialysis-dependent chronic kidney disease: a cross-sectional study.
Tanaka S; Kitamura H; Tsuruya K; Kitazono T; Nakano T;
Clin Exp Nephrol; 2022 Sep; 26(9):867-879. PubMed ID: 35507237
[TBL] [Abstract][Full Text] [Related]
6. A randomized, placebo-controlled trial of pentoxifylline on erythropoiesis-stimulating agent hyporesponsiveness in anemic patients with CKD: the Handling Erythropoietin Resistance With Oxpentifylline (HERO) trial.
Johnson DW; Pascoe EM; Badve SV; Dalziel K; Cass A; Clarke P; Ferrari P; McDonald SP; Morrish AT; Pedagogos E; Perkovic V; Reidlinger D; Scaria A; Walker R; Vergara LA; Hawley CM;
Am J Kidney Dis; 2015 Jan; 65(1):49-57. PubMed ID: 25115616
[TBL] [Abstract][Full Text] [Related]
7. A population-based study comparing biosimilar versus originator erythropoiesis-stimulating agent consumption in 6,117 patients with renal anaemia.
Hörbrand F; Bramlage P; Fischaleck J; Hasford J; Brunkhorst R
Eur J Clin Pharmacol; 2013 Apr; 69(4):929-36. PubMed ID: 23052412
[TBL] [Abstract][Full Text] [Related]
8. Minor Elevation in C-Reactive Protein Levels Predicts Incidence of Erythropoiesis-Stimulating Agent Hyporesponsiveness among Hemodialysis Patients.
Kimachi M; Fukuma S; Yamazaki S; Yamamoto Y; Akizawa T; Akiba T; Saito A; Fukuhara S
Nephron; 2015; 131(2):123-30. PubMed ID: 26344924
[TBL] [Abstract][Full Text] [Related]
9. Regional Variation of Erythropoiesis-Stimulating Agent Hyporesponsiveness in the Global Daprodustat Dialysis Study (ASCEND-D).
Macdougall IC; Meadowcroft AM; Blackorby A; Cizman B; Cobitz AR; Godoy S; Jha V; Johansen KL; McMahon G; Obrador GT; Wong MG; Singh AK
Am J Nephrol; 2023; 54(1-2):1-13. PubMed ID: 36739866
[TBL] [Abstract][Full Text] [Related]
10. Rationale and design of oBservational clinical Research In chronic kidney disease patients with renal anemia: renal proGnosis in patients with Hyporesponsive anemia To Erythropoiesis-stimulating agents, darbepoetiN alfa (BRIGHTEN Trial).
Kato H; Nangaku M; Hirakata H; Wada T; Hayashi T; Sato H; Yamazaki Y; Masaki T; Kagimura T; Yamamoto H; Hase H; Kamouchi M; Imai E; Mizuno K; Iwasaki M; Akizawa T; Tsubakihara Y; Maruyama S; Narita I
Clin Exp Nephrol; 2018 Feb; 22(1):78-84. PubMed ID: 28660446
[TBL] [Abstract][Full Text] [Related]
11. Protocol of a randomized controlled trial of an erythropoietin stimulating agent decision aid for anemia treatment in kidney disease.
Beach LB; Wild M; Ramachandran G; Ikizler HO; Cavanaugh KL
BMC Nephrol; 2016 Jul; 17(1):86. PubMed ID: 27430294
[TBL] [Abstract][Full Text] [Related]
12. Direct healthcare costs of chronic kidney disease management in Italy: What cost-savings can be achieved with higher biosimilar uptake and more appropriate use of erythropoiesis-stimulating agents?
Ingrasciotta Y; Sultana J; Formica D; Ientile V; Aiello A; Chinellato A; Tari DU; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Rossi M; Santoro D; Trifirò G;
Pharmacoepidemiol Drug Saf; 2021 Jan; 30(1):65-77. PubMed ID: 33067914
[TBL] [Abstract][Full Text] [Related]
13. Effectiveness and Safety of Switching Originator and Biosimilar Epoetins in Patients with Chronic Kidney Disease in a Large-Scale Italian Cohort Study.
Belleudi V; Trotta F; Addis A; Ingrasciotta Y; Ientile V; Tari M; Gini R; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Trifirò G;
Drug Saf; 2019 Dec; 42(12):1437-1447. PubMed ID: 31228010
[TBL] [Abstract][Full Text] [Related]
14. Soluble Fas affects erythropoiesis in vitro and acts as a potential predictor of erythropoiesis-stimulating agent therapy in patients with chronic kidney disease.
Chiloff DM; de Almeida DC; Dalboni MA; Canziani ME; George SK; Morsi AM; El-Akabawy N; Porada CD; Durao MS; Zarjou A; Almeida-Porada G; Goes MA
Am J Physiol Renal Physiol; 2020 Apr; 318(4):F861-F869. PubMed ID: 32003597
[TBL] [Abstract][Full Text] [Related]
15. Factors precipitating erythropoiesis-stimulating agent responsiveness in a European haemodialysis cohort: case-crossover study.
Gillespie IA; Macdougall IC; Richards S; Jones V; Marcelli D; Froissart M; Eckardt KU;
Pharmacoepidemiol Drug Saf; 2015 Apr; 24(4):414-26. PubMed ID: 25690434
[TBL] [Abstract][Full Text] [Related]
16. Comparative effectiveness and safety of erythropoiesis-stimulating agents (biosimilars vs originators) in clinical practice: a population-based cohort study in Italy.
Trotta F; Belleudi V; Fusco D; Amato L; Mecozzi A; Mayer F; Sansone M; Davoli M; Addis A
BMJ Open; 2017 Mar; 7(3):e011637. PubMed ID: 28283484
[TBL] [Abstract][Full Text] [Related]
17. Effect of erythropoiesis-stimulating agents on healthcare utilization, costs, and outcomes in chronic kidney disease.
Maddux FW; Shetty S; del Aguila MA; Nelson MA; Murray BM
Ann Pharmacother; 2007 Nov; 41(11):1761-9. PubMed ID: 17895328
[TBL] [Abstract][Full Text] [Related]
18. The Use of Erythropoiesis-Stimulating Agents in Patients With CKD and Cancer: A Clinical Approach.
Thavarajah S; Choi MJ
Am J Kidney Dis; 2019 Nov; 74(5):667-674. PubMed ID: 31395400
[TBL] [Abstract][Full Text] [Related]
19. In Search of Predictors of Switching Between Erythropoiesis-Stimulating Agents in Clinical Practice: A Multi-Regional Cohort Study.
Ingrasciotta Y; Belleudi V; Trotta F; Addis A; Fontana A; Chinellato A; Ientile V; Tari DU; Roberto G; Pastorello M; Scondotto S; Cananzi P; Traversa G; Davoli M; Rossi M; Trifirò G;
BioDrugs; 2020 Feb; 34(1):55-64. PubMed ID: 31595485
[TBL] [Abstract][Full Text] [Related]
20. Responsiveness to erythropoiesis-stimulating agents and renal survival in patients with chronic kidney disease.
Kuwahara M; Mandai S; Kasagi Y; Kusaka K; Tanaka T; Shikuma S; Akita W
Clin Exp Nephrol; 2015 Aug; 19(4):598-605. PubMed ID: 25183365
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
